A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia (NCT05952037)
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (72 Sites)
Showing the first 25 of 72 sites.
- City of Hope National Medical Center — Duarte, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Medstar Georgetown University Hospital — Washington D.C., District of Columbia
- University of Miami — Miami, Florida
- Northwestern Medicine Cancer Center — Warrenville, Illinois
- Mission Cancer and Blood — Waukee, Iowa
- University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- Hattiesburg Hematology and Oncology Clinic — Hattiesburg, Mississippi
- Memorial Sloan Kettering Cancer Center Mskcc — New York, New York
- Atrium Health Levine Cancer Institute (Lci) — Charlotte, North Carolina
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Ut Southwestern Medical Center — Dallas, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
- Virginia Commonwealth University Massey Cancer Center — Richmond, Virginia
- University of Washington — Seattle, Washington
- Concord Repatriation General Hospital — Concord, New South Wales
- Genesiscare North Shore — St Leonards, New South Wales
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Flinders Medical Centre — Bedford PK, South Australia
- Monash Health — Clayton, Victoria
- St Vincents Hospital Melbourne — Fitzroy, Victoria
- Linear Clinical Research — Nedlands, Western Australia
- Royal Perth Hospital — Perth, Western Australia
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Waldenstrom Macroglobulinemia
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom — Los Angeles, California
- Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia — Boston, Massachusetts
- Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer — Bethesda, Maryland
- Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia — Calgary, Alberta
- Ibrutinib + Venetoclax in Untreated WM — Boston, Massachusetts
Explore by condition: All Waldenstrom Macroglobulinemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.